-
-
Notifications
You must be signed in to change notification settings - Fork 1
/
Copy path_baseline.ris
3535 lines (3519 loc) · 273 KB
/
_baseline.ris
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
TY - JOUR
AB - This systematic review and meta-analysis aimed to quantify the diagnostic performance of pancreatic venous sampling (PVS), selective pancreatic arterial calcium stimulation with hepatic venous sampling (ASVS), and 18F-DOPA positron emission tomography (PET) in diagnosing and localizing focal congenital hyperinsulinism (CHI). This systematic review and meta-analysis was conducted according to the PRISMA statement. PubMed, EMBASE, SCOPUS and Web of Science electronic databases were systematically searched from their inception to November 1, 2011. Using predefined inclusion and exclusion criteria, two blinded reviewers selected articles. Critical appraisal ranked the retrieved articles according to relevance and validity by means of the QUADAS-2 criteria. Pooled data of homogeneous study results estimated the sensitivity, specificity, likelihood ratios and diagnostic odds ratio (DOR). 18F-DOPA PET was superior in distinguishing focal from diffuse CHI (summary DOR, 73.2) compared to PVS (summary DOR, 23.5) and ASVS (summary DOR, 4.3). Furthermore, it localized focal CHI in the pancreas more accurately than PVS and ASVS (pooled accuracy, 0.82 vs. 0.76, and 0.64, respectively). Important limitations comprised the inclusion of studies with small sample sizes, high probability of bias and heterogeneity among their results. Studies with small sample sizes and high probability of bias tended to overestimate the diagnostic accuracy. This systematic review and meta-analysis found evidence for the superiority of 18F-DOPA PET in diagnosing and localizing focal CHI in patients requiring surgery for this disease.
AU - Blomberg, Björn A.
AU - Moghbel, Mateen
AU - Saboury, Babak
AU - Stanley, Charles A.
AU - Alavi, Abass
CY - Netherlands
DA - 2012/07/03
DO - 10.1007/s11307-012-0572-0
EP - 105
ID - 000-463-679-101-319
IS - 1
JF - Molecular imaging and biology
L2 - https://paperity.org/p/8646823/the-value-of-radiologic-interventions-and-18f-dopa-pet-in-diagnosing-and-localizing-focal
L2 - https://link.springer.com/article/10.1007/s11307-012-0572-0/fulltext.html
L2 - https://core.ac.uk/display/81100392
L1 - https://link.springer.com/content/pdf/10.1007%2Fs11307-012-0572-0.pdf
L2 - https://europepmc.org/article/MED/22752652
L2 - https://pubmed.ncbi.nlm.nih.gov/22752652/
L2 - https://rd.springer.com/article/10.1007/s11307-012-0572-0
L2 - http://www.ncbi.nlm.nih.gov/pubmed/22752652
L2 - https://link.springer.com/article/10.1007/s11307-012-0572-0
PB - Springer New York
PY - 2012
SN - 18602002
SN - 15361632
SP - 97
TI - The Value of Radiologic Interventions and 18 F-DOPA PET in Diagnosing and Localizing Focal Congenital Hyperinsulinism: Systematic Review and Meta-Analysis
UR - https://lens.org/000-463-679-101-319
VL - 15
ER -
TY - JOUR
AB - Electrochemotherapy (ECT) is a local ablative treatment that is based on the reversible electroporation and intracellular accumulation of hydrophilic drug molecules, which greatly increases their cytotoxicity. In mucosal head and neck cancer (HNC), experience with ECT is limited due to the poor accessibility of tumors. In order to review the experience with ECT in mucosal HNC, we undertook a systematic review of the literature. In 22 articles, published between 1998 and 2020, 16 studies with 164 patients were described. Curative and palliative intent treatment were given to 36 (22%) and 128 patients (78%), respectively. The majority of tumors were squamous cell carcinomas (79.3%) and located in the oral cavity (62.8%). In the curative intent group, complete response after one ECT treatment was achieved in 80.5% of the patients, and in the palliative intent group, the objective (complete and partial) response rate was 73.1% (31.2% and 41.9%). No serious adverse events were reported during or soon after ECT and late effects were rare (19 events in 17 patients). The quality-of-life assessments did not show a significant deterioration at 12 months post-ECT. Provided these preliminary data are confirmed in randomized controlled trials, ECT may be an interesting treatment option in selected patients with HNC not amenable to standard local treatment.
AU - Strojan, Primož
AU - Grošelj, Aleš
AU - Sersa, Gregor
AU - Plaschke, Christina Caroline
AU - Vermorken, Jan B.
AU - Nuyts, Sandra
AU - de Bree, Remco
AU - Eisbruch, Avraham
AU - Mendenhall, William M.
AU - Smee, Robert
AU - Ferlito, Alfio
CY - Switzerland
DA - 2021/03/12
DO - 10.3390/cancers13061254
ID - 001-955-724-285-100
IS - 6
JF - Cancers
KW - electrochemotherapy
KW - head and neck cancer
KW - quality of life
KW - systematic review
L2 - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7999968
L2 - https://europepmc.org/article/PMC/PMC7999968
L1 - https://www.mdpi.com/2072-6694/13/6/1254/pdf
L2 - https://www.mdpi.com/2072-6694/13/6/1254
PB - Multidisciplinary Digital Publishing Institute (MDPI)
PY - 2021
SN - 20726694
SP - 1254
TI - Electrochemotherapy in Mucosal Cancer of the Head and Neck: A Systematic Review.
UR - https://lens.org/001-955-724-285-100
VL - 13
ER -
TY - JOUR
AB - Introduction Diabetes monitoring systems (DMS) are a possible approach for regular control of glucose levels in patients with Type 1 or 2 diabetes in order to improve therapeutic outcomes or to identify and modify inappropriate patient behaviors in a timely manner. Despite the significant number of studies observing the DMS, no collective evidence is available about the effect of all devices. Goal To review and consolidate evidences from multiple systematic reviews on the diabetes monitoring systems and the outcomes achieved. Materials and methods Internet-based search in PubMed, EMBASE, and Cochrane was performed to identify all studies relevant to the research question. The data regarding type of intervention, type of diabetes mellitus, type of study, change in clinical parameter(s), or another relevant outcome were extracted and summarized. Results Thirty-three out of 1,495 initially identified studies, involving more than 44,100 patients with Type 1, Type 2, or gestational diabetes for real-time or retrospective Continuous Glucose Monitoring (CGMS), Sensor Augmented Pump Therapy (SAPT), Self-monitoring Blood Glucose (SMBG), Continuous subcutaneous insulin infusion (CSII), Flash Glucose Monitoring (FGM), Closed-loop systems and telemonitoring, were included. Most of the studies observed small nominal effectiveness of DMS. In total 11 systematic reviews and 15 meta-analyses, with most focusing on patients with Type 1 diabetes (10 and 6, respectively), reported a reduction in glycated hemoglobin (HbA1c) levels from 0.17 to 0.70% after use of DMS. Conclusion Current systematic review of already published systematic reviews and meta-analyses suggests that no statistically significant difference exists between the values of HbA1c as a result of application of any type of DMS. The changes in HbA1c values, number and frequency of hypoglycemic episodes, and time in glucose range are the most valuable for assessing the appropriateness and effectiveness of DMS. Future more comprehensive studies assessing the effectiveness, cost-effectiveness, and comparative effectiveness of DMS are needed to stratify them for the most suitable diabetes patients' subgroups.
AU - Kamusheva, Maria
AU - Tachkov, Konstantin
AU - Dimitrova, Maria
AU - Mitkova, Zornitsa
AU - García-Sáez, Gema
AU - Hernando, M. Elena
AU - Goettsch, Wim G.
AU - Petrova, Guenka
CY - Switzerland
DA - 2021/03/16
DO - 10.3389/fendo.2021.636959
EP - 636959
ID - 002-042-026-423-65X
JF - Frontiers in endocrinology
KW - diabetes
KW - diabetes monitoring systems
KW - glucose control
KW - personalized approach
KW - systematic review
L2 - https://pubmed.ncbi.nlm.nih.gov/33796074/
L2 - https://europepmc.org/article/PMC/PMC8008960
L2 - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8008960
L2 - https://www.frontiersin.org/articles/10.3389/fendo.2021.636959/full
L2 - https://www.ncbi.nlm.nih.gov/pubmed/33796074
PB - Frontiers Media S.A.
PY - 2021
SN - 16642392
SP - 636959
TI - A Systematic Review of Collective Evidences Investigating the Effect of Diabetes Monitoring Systems and Their Application in Health Care.
UR - https://lens.org/002-042-026-423-65X
VL - 12
ER -
TY - JOUR
AU - Doesschate, T. ten
AU - van der Vaart, T.W.
AU - Damen, Johanna A A G
AU - Bonten, Marc J. M.
AU - van Werkhoven, C.H.
CY - United Kingdom
DA - 2020/08/12
DO - 10.1016/j.jinf.2020.08.008
EP - 509
ID - 002-582-554-884-860
IS - 4
JF - The Journal of infection
L2 - https://www.ncbi.nlm.nih.gov/pubmed/32795483
L2 - https://pubmed.ncbi.nlm.nih.gov/32795483/
L2 - https://www.sciencedirect.com/science/article/pii/S0163445320305417
PB - W.B. Saunders Ltd
PY - 2020
SN - 15322742
SN - 01634453
SP - 499
TI - Carbapenem-alternative strategies for complicated urinary tract infections: A systematic review of randomized controlled trials.
UR - https://lens.org/002-582-554-884-860
VL - 81
ER -
TY - JOUR
AB - Background Insight in sex disparities in the detection of cardiovascular risk factors and diabetes-related complications may improve diabetes care. The aim of this systematic review is to study whether sex disparities exist in the assessment of cardiovascular risk factors and screening for diabetes-related complications. Methods PubMed was systematically searched up to April 2020, followed by manual reference screening and citations checks (snowballing) using Google Scholar. Observational studies were included if they reported on the assessment of cardiovascular risk factors (HbA1c, lipids, blood pressure, smoking status, or BMI) and/or screening for nephropathy, retinopathy, or performance of feet examinations, in men and women with diabetes separately. Studies adjusting their analyses for at least age, or when age was considered as a covariable but left out from the final analyses for various reasons (i.e. backward selection), were included for qualitative analyses. No meta-analyses were planned because substantial heterogeneity between studies was expected. A modified Newcastle-Ottawa Quality Assessment Scale for cohort studies was used to assess risk of bias. Results Overall, 81 studies were included. The majority of the included studies were from Europe or North America (84%).The number of individuals per study ranged from 200 to 3,135,019 and data were extracted from various data sources in a variety of settings. Screening rates varied considerably across studies. For example, screening rates for retinopathy ranged from 13% to 90%, with half the studies reporting screening rates less than 50%. Mixed findings were found regarding the presence, magnitude, and direction of sex disparities with regard to the assessment of cardiovascular risk factors and screening for diabetes-related complications, with some evidence suggesting that women, compared with men, may be more likely to receive retinopathy screening and less likely to receive foot exams. Conclusion Overall, no consistent pattern favoring men or women was found with regard to the assessment of cardiovascular risk factors and screening for diabetes-related complications, and screening rates can be improved for both sexes.
AU - de Jong, Marit
AU - Peters, Sanne A.E.
AU - de Ritter, Rianneke
AU - van der Kallen, Carla J. H.
AU - Sep, Simone J. S.
AU - Woodward, Mark
AU - Stehouwer, Coen D.A.
AU - Bots, Michiel L.
AU - Vos, Rimke C.
CY - Switzerland
DA - 2021/03/30
DO - 10.3389/fendo.2021.617902
EP - 617902
ID - 004-848-996-111-636
JF - Frontiers in endocrinology
KW - diabetes
KW - diabetes-related complications
KW - healthcare provision
KW - risk factors
KW - screening
KW - sex disparities
KW - systematic review
L2 - https://pubmed.ncbi.nlm.nih.gov/33859615/
L2 - https://europepmc.org/article/MED/33859615
L2 - https://www.ncbi.nlm.nih.gov/pubmed/33859615
L2 - https://cris.maastrichtuniversity.nl/en/publications/sex-disparities-in-cardiovascular-risk-factor-assessment-and-scre
L2 - https://www.frontiersin.org/articles/10.3389/fendo.2021.617902/full
PB - Frontiers Media S.A.
PY - 2021
SN - 16642392
SP - 617902
TI - Sex Disparities in Cardiovascular Risk Factor Assessment and Screening for Diabetes-Related Complications in Individuals With Diabetes: A Systematic Review.
UR - https://lens.org/004-848-996-111-636
VL - 12
ER -
TY - JOUR
AB - To systematically review the value of apparent diffusion coefficient (ADC) measurement in the differentiation between benign and malignant lesions. A systematic search of the Medline/Pubmed and Embase databases revealed 109 relevant studies. Quality of these articles was assessed using the Quality Assessment of the Studies of Diagnostic Accuracy Included in Systematic Reviews (QUADAS) criteria. Reported ADC values of benign and malignant lesions were compared per organ. The mean quality score of the reviewed articles was 50%. Comparison of ADC values showed marked variation among studies and between benign and malignant lesions in various organs. In several organs, such as breast, liver, and uterus, ADC values discriminated well between benign and malignant lesions. In other organs, such as the salivary glands, thyroid, and pancreas, ADCs were not significantly different between benign and malignant lesions. The potential utility of ADC measurement for the characterisation of tumours differs per organ. Future well-designed studies are required before ADC measurements can be recommended for the differentiation of benign and malignant lesions. These future studies should use standardised acquisition protocols and provide complete reporting of study methods, to facilitate comparison of results and clinical implementation of ADC measurement for tumour characterisation.
AU - Vermoolen, M. A.
AU - Kwee, Thomas C.
AU - Nievelstein, R. A. J.
CY - Germany
DA - 2012/06/07
DO - 10.1007/s13244-012-0175-y
EP - 409
ID - 004-868-562-022-693
IS - 4
JF - Insights into imaging
L2 - https://insightsimaging.springeropen.com/articles/10.1007/s13244-012-0175-y
L2 - https://europepmc.org/articles/PMC3481080
L2 - https://core.ac.uk/display/81710421
L1 - https://link.springer.com/content/pdf/10.1007%2Fs13244-012-0175-y.pdf
L2 - https://link.springer.com/article/10.1007/s13244-012-0175-y
L2 - https://www.ncbi.nlm.nih.gov/pubmed/22695951
L2 - https://www.deepdyve.com/lp/springer-journals/apparent-diffusion-coefficient-measurements-in-the-differentiation-4LSQ0JkRc6
L2 - https://paperity.org/p/4117806/apparent-diffusion-coefficient-measurements-in-the-differentiation-between-benign-and
L2 - https://pubmed.ncbi.nlm.nih.gov/22695951/
PB - Springer Science and Business Media Deutschland GmbH
PY - 2012
SN - 18694101
SP - 395
TI - Apparent diffusion coefficient measurements in the differentiation between benign and malignant lesions: a systematic review.
UR - https://lens.org/004-868-562-022-693
VL - 3
ER -
TY - JOUR
AB - Worldwide physical activity levels of adults are declining, which is associated with increased chronic disease risk. Wearables and smartphone applications offer new opportunities to change physical activity behaviour. This systematic review summarizes the evidence regarding the effect of wearables and smartphone applications on promoting physical activity. PubMed, EMBASE and Cochrane databases were searched for RCTs, published since January 2008, on wearables and smartphone applications to promote physical activity. Studies were excluded when the study population consisted of children or adolescents, the intervention did not promote physical activity or comprised a minor part of the intervention, or the intervention was Internet-based and not accessible by smartphone. Risk of bias was assessed by the Cochrane collaboration tool. The primary outcome was changed in physical activity level. Meta-analyses were performed to assess the pooled effect on (moderate-to-vigorous) physical activity in minutes per day and daily step count. Eighteen RCTs were included. Use of wearables and smartphone applications led to a small to moderate increase in physical activity in minutes per day (SMD = 0.43, 95% CI = 0.03 to 0.82; I2 = 85%) and a moderate increase in daily step count (SMD = 0.51, 95% CI = 0.12 to 0.91; I2 = 90%). When removing studies with an unclear or high risk of bias, intervention effects improved and statistical heterogeneity was removed. This meta-analysis showed a small to moderate effect of physical activity interventions comprising wearables and smartphone applications on physical activity. Hence, wearables and smartphone applications are likely to bring new opportunities in delivering tailored interventions to increase levels of physical activity.
AU - Gal, Roxanne
AU - May, Anne M.
AU - van Overmeeren, Elon J.
AU - Simons, Monique
AU - Monninkhof, Evelyn M.
CY - Switzerland
DA - 2018/09/03
DO - 10.1186/s40798-018-0157-9
EP - 42
ID - 005-657-406-851-39X
IS - 1
JF - Sports medicine - open
KW - Physical activity
KW - Smartphone applications
KW - Wearables
L2 - https://europepmc.org/article/MED/30178072
L2 - https://www.narcis.nl/publication/RecordID/oai%3Ascholarlypublications.universiteitleiden.nl%3Aitem_2971586
L2 - https://pubmed.ncbi.nlm.nih.gov/30178072/
L2 - https://sportsmedicine-open.springeropen.com/articles/10.1186/s40798-018-0157-9
L2 - http://dspace.library.uu.nl/handle/1874/371715
L1 - https://link.springer.com/content/pdf/10.1186/s40798-018-0157-9.pdf
L2 - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6120856
L2 - https://link.springer.com/article/10.1186/s40798-018-0157-9
L2 - http://www.ncbi.nlm.nih.gov/pubmed/30178072
L2 - https://link.springer.com/article/10.1186/s40798-018-0157-9/figures/5
PB - Springer Science and Business Media LLC
PY - 2018
SN - 21991170
SN - 21989761
SP - 42
TI - The Effect of Physical Activity Interventions Comprising Wearables and Smartphone Applications on Physical Activity: a Systematic Review and Meta-analysis
UR - https://lens.org/005-657-406-851-39X
VL - 4
ER -
TY - JOUR
AB - Health-related quality of life (HRQoL) assessments are increasingly incorporated into oncological randomized controlled trials (RCTs). The quality of HRQoL reporting in RCTs concerning palliative systemic treatment for advanced esophagogastric cancer is currently unknown. Therefore, we conducted a systematic review to investigate the quality of HRQoL reporting over time. PubMed, CENTRAL and EMBASE were searched for RCTs concerning systemic treatment for advanced esophagogastric cancer up to February 2017. The Minimum Standard Checklist for Evaluating HRQoL Outcomes in Cancer Clinical Trials was used to rate the quality of HRQoL reporting. Univariate and multivariate generalized linear regression analysis was used to investigate factors affecting the quality of reporting over time. In total, 37 original RCTs (N = 10,887 patients) were included. The quality of reporting was classified as ‘very limited’ in 4 studies (11%), ‘limited’ in 24 studies (65%), and ‘probably robust’ in 9 studies (24%). HRQoL reporting did not improve over time, and it did not improve following the publication of the CONSORT-PRO statement in 2013. The publication of HRQoL findings in a separate article and second-line treatment were associated with better reporting. HRQoL reporting in RCTs concerning palliative systemic therapy for advanced esophagogastric cancer is limited and has not improved over time. This systematic review provides specific recommendations for authors to improve HRQoL reporting: formulate hypotheses a priori, clearly describe instrument administration, and handle missing data and interpret findings appropriately.
AU - Veer, Emil ter
AU - van Kleef, Jessy Joy
AU - Sprangers, Mirjam A. G.
AU - Mohammad, Nadia Haj
AU - van Oijen, Martijn G.H.
AU - van Laarhoven, Hanneke W. M.
CY - Germany
DA - 2018/01/29
DO - 10.1007/s10120-018-0792-3
EP - 195
ID - 006-338-538-001-600
IS - 2
JF - Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
KW - Esophageal cancer
KW - Gastric cancer
KW - Quality of life
KW - Randomized controlled trial
KW - Systemic therapy
L2 - https://core.ac.uk/display/153324547
L2 - https://pubmed.ncbi.nlm.nih.gov/29380191/
L2 - https://paperity.org/p/86173729/reporting-of-health-related-quality-of-life-in-randomized-controlled-trials-involving
L2 - https://link.springer.com/article/10.1007/s10120-018-0792-3
L2 - https://www.narcis.nl/publication/RecordID/oai%3Apure.amc.nl%3Apublications%2Fee58081a-37ac-4e21-a6a2-f3c7fc13a68e
L1 - https://link.springer.com/content/pdf/10.1007%2Fs10120-018-0792-3.pdf
L2 - https://www.ncbi.nlm.nih.gov/pubmed/29380191
L2 - https://europepmc.org/abstract/MED/29380191
PB - Springer Japan
PY - 2018
SN - 14363305
SN - 14363291
SP - 183
TI - Reporting of health-related quality of life in randomized controlled trials involving palliative systemic therapy for esophagogastric cancer: a systematic review.
UR - https://lens.org/006-338-538-001-600
VL - 21
ER -
TY - JOUR
AB - This study aimed to systematically review the prognostic value of interim and end-of-treatment 18F-fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) in follicular lymphoma during and after first-line therapy. The PubMed/MEDLINE database was searched for relevant original studies. Included studies were methodologically assessed, and their results were extracted and descriptively analyzed. Three studies on the prognostic value of interim FDG-PET and eight studies on the prognostic value of end-of-treatment FDG-PET were included. Overall, studies were of poor methodological quality. In addition, there was incomplete reporting of progression-free survival (PFS) and overall survival (OS) data by several studies, and none of the studies incorporated the Follicular Lymphoma International Prognostic Index (FLIPI) in the OS analyses. Two studies reported no significant difference in PFS between interim FDG-PET positive and negative patients, whereas one study reported a significant difference in PFS between the two groups. Two studies reported no significant difference in OS between interim FDG-PET positive and negative patients. Five studies reported end-of-treatment FDG-PET positive patients to have a significantly worse PFS than end-of-treatment FDG-PET negative patients, and one study reported a non-significant trend towards a worse PFS for end-of-treatment FDG-PET positive patients. Three studies reported end-of-treatment FDG-PET positive patients to have a significantly worse OS than end-of-treatment FDG-PET negative patients. In conclusion, the available evidence does not support the use of interim FDG-PET in follicular lymphoma. Although published studies suggest end-of-treatment FDG-PET to be predictive of PFS and OS, they suffer from numerous biases and failure to correct OS prediction for the FLIPI.
AU - Adams, Hugo J. A.
AU - Nievelstein, Rutger A.J.
AU - Kwee, Thomas C.
CY - Germany
DA - 2015/11/18
DO - 10.1007/s00277-015-2553-2
EP - 18
ID - 007-189-812-368-705
IS - 1
JF - Annals of hematology
KW - End-of-treatment
KW - FDG-PET
KW - Follicular lymphoma
KW - Interim
KW - Systematic review
L2 - https://rd.springer.com/article/10.1007/s00277-015-2553-2
L2 - https://core.ac.uk/display/81265768
L2 - http://dspace.library.uu.nl/handle/1874/332413
L2 - https://www.ncbi.nlm.nih.gov/pubmed/26576560
L2 - https://www.narcis.nl/publication/RecordID/oai%3Adspace.library.uu.nl%3A1874%2F332413
L1 - https://link.springer.com/content/pdf/10.1007%2Fs00277-015-2553-2.pdf
L2 - https://dspace.library.uu.nl/bitstream/1874/332413/1/2.pdf
L2 - https://link.springer.com/article/10.1007/s00277-015-2553-2/fulltext.html
L2 - https://link.springer.com/article/10.1007/s00277-015-2553-2
L2 - https://pubmed.ncbi.nlm.nih.gov/26576560/
L2 - https://europepmc.org/article/MED/26576560
PB - Springer Verlag
PY - 2015
SN - 14320584
SN - 09395555
SP - 11
TI - Prognostic value of interim and end-of-treatment FDG-PET in follicular lymphoma: a systematic review
UR - https://lens.org/007-189-812-368-705
VL - 95
ER -
TY - JOUR
AB - Abstract Objectives The objective of the study was to examine whether clinical trials that have been included in systematic reviews have been registered in clinical trial registers and, when they have, whether results of the trials were included in the clinical trial register. Study Design and Setting This study used a sample of 100 systematic reviews published by the Cochrane Musculoskeletal, Oral, Skin and Sensory Network between 2014 and 2019. Results We identified 2,000 trials (369,778 participants) from a sample of 100 systematic reviews. The median year of trial publication was 2007. Of 1,177 trials published in 2005 or later, a clinical trial registration record was identified for 368 (31%). Of these registered trials, 135 (37%) were registered prospectively and results were posted for 114 (31%); most registered trials evaluated pharmaceutical interventions (62%). Of trials published in the last 10 years, the proportion of registered trials increased to 38% (261 of 682). Conclusion Although some improvement in clinical trial registration has been observed in recent years, the proportion of registered clinical trials included in recently published systematic reviews remains less than desirable. Prospective clinical trial registration provides an essential role in assessing the risk of bias and judging the quality of evidence in systematic reviews of intervention safety and effectiveness.
AU - Lindsley, Kristina
AU - Fusco, Nicole
AU - Teeuw, Hannah
AU - Mooij, Eva
AU - Scholten, Rob J.P.M.
AU - Hooft, Lotty
CY - Netherlands
DA - 2020/12/14
DO - 10.1016/j.jclinepi.2020.12.016
EP - 87
ID - 007-825-786-971-176
JF - Journal of clinical epidemiology
KW - Evidence synthesis
KW - Randomized controlled trial
KW - Systematic review
KW - Trial registration
L2 - https://pubmed.ncbi.nlm.nih.gov/33333165/
L2 - https://www.sciencedirect.com/science/article/abs/pii/S0895435620312208
L2 - https://www.sciencedirect.com/science/article/pii/S0895435620312208
PB - Elsevier USA
PY - 2020
SN - 18785921
SN - 08954356
SP - 79
TI - Poor compliance of clinical trial registration among trials included in systematic reviews: a cohort study.
UR - https://lens.org/007-825-786-971-176
VL - 132
ER -
TY - JOUR
AB - Background: The European Academy of Allergy and Clinical Immunology (EAACI) is developing Guidelines on Allergen
Immunotherapy (AIT) for Allergic Rhinoconjunctivitis (ARC). To inform the development of recommendations, we
sought to critically assess the systematic review evidence on the effectiveness, safety and cost-effectiveness of AIT for
ARC.
Methods: We undertook a systematic overview, which involved searching nine international biomedical databases
from inception to October 31, 2015. Studies were independently screened by two reviewers against pre-defined eligibility
criteria and critically appraised using the Critical Appraisal Skills Programme (CASP) Systematic Review Checklist
for systematic reviews. Data were descriptively synthesized.
Results: Our searches yielded a total of 5932 potentially eligible studies, from which 17 systematic reviews met
our inclusion criteria. Eight of these were judged to be of high, five moderate and three low quality. These reviews
suggested that, in carefully selected patients, subcutaneous (SCIT) and sublingual (SLIT) immunotherapy resulted in
significant reductions in symptom scores and medication requirements. Serious adverse outcomes were rare for both
SCIT and SLIT. Two systematic reviews reported some evidence of potential cost savings associated with use of SCIT
and SLIT.
Conclusions: We found moderate-to-strong evidence that SCIT and SLIT can, in appropriately selected patients,
reduce symptoms and medication requirements in patients with ARC with reassuring safety data. This evidence does
however need to be interpreted with caution, particularly given the heterogeneity in the populations, allergens and
protocols studied . There is a lack of data on the relative effectiveness, cost-effectiveness and safety of SCIT and SLIT.
We are now systematically reviewing all the primary studies, including recent evidence that has not been incorporated
into the published systematic reviews.
AU - Nurmatov, Ulugbek
AU - Dhami, Sangeeta
AU - Arasi, Stefania
AU - Roberts, Graham
AU - Pfaar, Oliver
AU - Muraro, Antonella
AU - Ansotegui, Ignacio J.
AU - Calderon, Moises A.
AU - Cingi, Cemal
AU - Durham, Stephen R.
AU - van Wijk, Roy Gerth
AU - Halken, Susanne
AU - Hamelmann, Eckard
AU - Hellings, Peter
AU - Jacobsen, Lars
AU - Knol, Edward F.
AU - Larenas-Linnemann, Désirée
AU - Lin, Sandra Y.
AU - Maggina, Vivian
AU - Oude-Elberink, Hanneke
AU - Pajno, Giovanni Battista
AU - Panwankar, Ruby
AU - Pastorello, Elideanna
AU - Pitsios, Constantinos
AU - Rotiroti, Giuseppina
AU - Timmermans, Frans
AU - Tsilochristou, Olympia
AU - Varga, Eva M.
AU - Wilkinson, Jamie
AU - Williams, Andrew
AU - Worm, Margitta
AU - Zhang, Luo
AU - Sheikh, Aziz
CY - United Kingdom
DA - 2017/08/08
DO - 10.1186/s13601-017-0159-6
EP - 24
ID - 007-914-278-171-898
IS - 1
JF - Clinical and translational allergy
KW - Allergen immunotherapy
KW - Allergic rhinitis
KW - Allergic rhinoconjuctivitis
KW - Allergy
KW - Hay fever
KW - Rhinitis
L1 - https://pure.rug.nl/ws/files/46989412/Allergen_immunotherapy_for_allergic_rhinoconjunctivitis_a_systematic_overview_of_systematic_reviews.pdf
L2 - http://dspace.library.uu.nl/handle/1874/356415
L2 - https://pubmed.ncbi.nlm.nih.gov/28794855/
L2 - https://link.springer.com/article/10.1186/s13601-017-0159-6
L2 - https://lirias.kuleuven.be/1187608
L2 - https://research.rug.nl/en/publications/allergen-immunotherapy-for-allergic-rhinoconjunctivitis-a-systema
L2 - https://www.ncbi.nlm.nih.gov/pubmed/28794855
L2 - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5547534
L1 - https://link.springer.com/content/pdf/10.1186/s13601-017-0159-6.pdf
L2 - https://orca.cardiff.ac.uk/103898/
L2 - https://www.research.ed.ac.uk/portal/en/publications/allergen-immunotherapy-for-allergic-rhinoconjunctivitis(aca296e6-92f6-4077-8db7-9137cc887809).html
L2 - https://www.rug.nl/research/portal/files/46989412/Allergen_immunotherapy_for_allergic_rhinoconjunctivitis_a_systematic_overview_of_systematic_reviews.pdf
L2 - https://jhu.pure.elsevier.com/en/publications/allergen-immunotherapy-for-allergic-rhinoconjunctivitis-a-systema-2
L2 - http://www.ncbi.nlm.nih.gov/pubmed/28794855
L2 - https://europepmc.org/article/MED/28794855
L2 - https://www.narcis.nl/publication/RecordID/oai%3Arepub.eur.nl%3A101320
L2 - https://core.ac.uk/display/154412648
L2 - https://dspace.library.uu.nl/bitstream/1874/356415/1/s13601_017_0159_6.pdf
L2 - http://orca.cf.ac.uk/103898/
L2 - https://ctajournal.biomedcentral.com/articles/10.1186/s13601-017-0159-6
L2 - https://repub.eur.nl/pub/101320
L1 - https://repub.eur.nl/pub/101320/REPUB_101320-OA.pdf
L2 - https://core.ac.uk/download/97016012.pdf
PB - BioMed Central
PY - 2017
SN - 20457022
SP - 24
TI - Allergen immunotherapy for allergic rhinoconjunctivitis : A systematic overview of systematic reviews
UR - https://lens.org/007-914-278-171-898
VL - 7
ER -
TY - JOUR
AB - Identifying a child with pneumonia in the large group of children with acute respiratory tract infections can be challenging for primary care physicians. Knowledge on the diagnostic value of specific signs and symptoms may guide future decision rules and guidelines for clinicians. We aimed to identify and systematically review available evidence for the diagnostic value of signs, symptoms, and additional tests to diagnose pneumonia in children in an ambulatory setting in developed countries. We conducted a systematic review, searching in the electronic databases of PubMed and Embase. Quality assessment of studies was done using the QUADAS-2 criteria. After data extraction from selected studies, we calculated and summarized test characteristics (sensitivity, specificity, negative and positive predictive values) of all available signs, symptoms, additional laboratory tests, and chest ultrasonography. The original search yielded 4665 records, of which 17 articles were eligible for analysis: 12 studies on signs and symptoms, 4 on additional laboratory tests, and 6 on ultrasonography. All included studies were performed in a secondary care setting. Risk of bias was present in the majority of studies in the domain of patient selection. Prevalence of pneumonia varied from 3.4% to 71.7%. The diagnostic value of the available 27 individual signs and symptoms to identify pneumonia was low. In a low prevalence setting, (4 studies, pneumonia prevalence 10%), additional diagnostic tests such as oxygen saturation, C-reactive protein, and white blood cell count are more promising. Chest ultrasonography showed high diagnostic value in settings with higher prevalence of pneumonia. Single signs and symptoms from medical history and physical examination or individual additional diagnostic tests are insufficient to diagnose pneumonia in ambulant children. Very few diagnostic studies are conducted in settings with low prevalence of pneumonia. Future research in low prevalence settings should focus on the diagnostic value of the combination of clinical features and additional testing possibly using meta-analysis of individual data.
AU - Schot, Marjolein J C
AU - Dekker, Anne R J
AU - Giorgi, Wesley G.
AU - Hopstaken, Rogier M.
AU - de Wit, Niek J.
AU - Verheij, Theo J M
AU - Cals, Jochen W L
CY - United Kingdom
DA - 2018/10/26
DO - 10.1038/s41533-018-0104-8
EP - 40
ID - 008-800-308-683-976
IS - 1
JF - NPJ primary care respiratory medicine
L2 - https://www.narcis.nl/publication/RecordID/oai%3Acris.maastrichtuniversity.nl%3Apublications%2Fca058201-014d-4d84-b308-59e03c197393
L2 - https://www.nature.com/articles/s41533-018-0104-8.pdf
L2 - http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6203790
L2 - https://dspace.library.uu.nl/bitstream/1874/372984/1/s41533_018_0104_8.pdf
L2 - http://dspace.library.uu.nl/handle/1874/372984
L2 - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6203790
L2 - http://europepmc.org/articles/PMC6203790
L2 - https://www.nature.com/articles/s41533-018-0104-8/
L2 - https://pubmed.ncbi.nlm.nih.gov/30367067/
PB - Nature Publishing Group
PY - 2018
SN - 20551010
SP - 40
TI - Diagnostic value of signs, symptoms and diagnostic tests for diagnosing pneumonia in ambulant children in developed countries: a systematic review.
UR - https://lens.org/008-800-308-683-976
VL - 28
ER -
TY - JOUR
AB - Background Congenital cytomegalovirus (cCMV) infection is a major cause of sensorineural hearing loss in children. Objective of review The objective of this systematic review was to compare performance in paediatric cochlear implant users with SNHL caused by cCMV compared to non-cCMV implantees. Type of review Systematic review SEARCH STRATEGY: PubMed, EMBASE and the Cochrane databases were searched from inception up to 15 May 2017 for children, cochlear implant, performance and their synonyms. Evaluation methods Titles, abstracts and full texts were screened for eligibility. Directness of evidence and risk of bias were assessed. From the included studies, study characteristics and outcome data (speech perception, speech production, receptive language and auditory performance of cCMV groups and non-cCMV groups) were extracted. Results A total of 5280 unique articles were screened of which 28 were eligible for critical appraisal. After critical appraisal, 12 studies remained for data extraction. Seven of 12 studies showed worse performance after cochlear implantation in cCMV children compared to non-cCMV children. Worse performance in cCMV children was attributed to cCMV-related comorbidities in six of these studies. Available data on asymptomatic cCMV children compared to non-cCMV children did not reveal an unfavourable effect on cochlear implant performance. Conclusions The available evidence reveals that cCMV children often have worse cochlear implant performance compared to non-cCMV children, which can be attributed to cCMV related comorbidities. We urge physicians to take into account the cCMV related comorbidities in the counselling of paediatric CI users deafened by cCMV.
AU - Kraaijenga, Véronique J. C.
AU - van Houwelingen, F.
AU - van der Horst, S.
AU - Visscher, J.
AU - Huisman, J.M.L.
AU - Hollman, E.J.
AU - Stegeman, Inge
AU - Smit, Adriana L.
CY - United Kingdom
DA - 2018/06/19
DO - 10.1111/coa.13142
EP - 1295
ID - 009-720-475-545-024
IS - 5
JF - Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery
KW - children
KW - cochlear implantation
KW - comorbidities
KW - congenital cytomegalovirus
KW - performance
KW - prelingual deafness
KW - sensorineural hearing loss
KW - systematic review
L2 - https://www.ncbi.nlm.nih.gov/pubmed/29768731
L2 - http://www.ncbi.nlm.nih.gov/pubmed/29768731
L1 - https://onlinelibrary.wiley.com/doi/pdf/10.1111/coa.13142
L2 - https://onlinelibrary.wiley.com/doi/full/10.1111/coa.13142
L2 - https://pubmed.ncbi.nlm.nih.gov/29768731/
PB - Wiley-Blackwell
PY - 2018
SN - 17494486
SN - 17494478
SP - 1283
TI - Cochlear implant performance in children deafened by congenital cytomegalovirus-A systematic review.
UR - https://lens.org/009-720-475-545-024
VL - 43
ER -
TY - JOUR
AB - Glioma patients suffer from a wide range of symptoms which influence quality of life negatively. The aim of this review is to give an overview of symptoms most prevalent in glioma patients throughout the total disease trajectory, to be used as a basis for the development of a specific glioma Patient Reported Outcome Measure (PROM) for early assessment and monitoring of symptoms in glioma patients. A systematic review focused on symptom prevalence in glioma patients in different phases of disease and treatment was performed in MEDLINE, CINAHL and EMBASE according to PRISMA recommendations. We calculated weighted means for prevalence rates per symptom. The search identified 2.074 unique papers, of which 32 were included in this review. In total 25 symptoms were identified. The ten most prevalent symptoms were: seizures (37%), cognitive deficits (36%), drowsiness (35%), dysphagia (30%), headache (27%), confusion (27%), aphasia (24%), motor deficits (21%), fatigue (20%) and dyspnea (20%). Eight out of ten of the most prevalent symptoms in glioma patients are related to the central nervous system and therefore specific for glioma. Our findings emphasize the importance of tailored symptom care for glioma patients and may aid in the development of specific PROMs for glioma patients in different phases of the disease.
AU - IJzerman-Korevaar, Margriet
AU - Snijders, Tom J.
AU - de Graeff, Alexander
AU - Teunissen, Saskia C.C.M.
AU - de Vos, Filip
CY - Netherlands
DA - 2018/10/30
DO - 10.1007/s11060-018-03015-9
EP - 496
ID - 012-124-483-362-604
IS - 3
JF - Journal of neuro-oncology
KW - Adverse events
KW - Glioblastoma
KW - Glioma
KW - PROM
KW - Patient reported outcomes
KW - Symptoms
KW - Toxicity
L2 - https://europepmc.org/article/MED/30377935
L2 - https://link.springer.com/article/10.1007/s11060-018-03015-9
L2 - https://www.ncbi.nlm.nih.gov/pubmed/30377935
L1 - https://link.springer.com/content/pdf/10.1007/s11060-018-03015-9.pdf
L2 - http://dspace.library.uu.nl/handle/1874/377077
L2 - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6267240/
L2 - http://www.ncbi.nlm.nih.gov/pubmed/30377935
L2 - https://www.narcis.nl/publication/RecordID/oai%3Adspace.library.uu.nl%3A1874%2F377077
PB - Kluwer Academic Publishers
PY - 2018
SN - 15737373
SN - 0167594x
SP - 485
TI - Prevalence of symptoms in glioma patients throughout the disease trajectory: a systematic review
UR - https://lens.org/012-124-483-362-604
VL - 140
ER -
TY - JOUR
AB - Increasing evidence indicates a relationship between cannabis use and psychosis risk. Specific factors, such as determinants of cannabis use or the genetic profile of cannabis users, appear to moderate this association. The present systematic review presents a detailed and up-to-date literature overview on factors that influence the relationship between cannabis use and psychosis risk. A systematic search was performed according to the PRISMA guidelines in MEDLINE and Embase, and 56 studies were included. The results show that, in particular, frequent cannabis use, especially daily use, and the consumption of high-potency cannabis are associated with a higher risk of developing psychosis. Moreover, several genotypes moderate the impact of cannabis use on psychosis risk, particularly those involved in the dopamine function, such as AKT1. Finally, cannabis use is associated with an earlier psychosis onset and increased risk of transition in individuals at a clinical high risk of psychosis. These findings indicate that changing cannabis use behavior could be a harm reduction strategy employed to lower the risk of developing psychosis. Future research should aim to further develop specific biomarkers and genetic profiles for psychosis, thereby contributing to the identification of individuals at the highest risk of developing a psychotic disorder.
AU - van der Steur, Sanne J
AU - Batalla, Albert
AU - Bossong, Matthijs G.
CY - Switzerland
DA - 2020/02/12
DO - 10.3390/brainsci10020097
ID - 012-151-107-325-934
IS - 2
JF - Brain sciences
KW - age of onset
KW - cannabis use
KW - clinical high risk
KW - genetics
KW - psychotic disorder
L2 - https://pubmed.ncbi.nlm.nih.gov/32059350/
L2 - http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7071602
L2 - https://www.mdpi.com/2076-3425/10/2/97/htm
L2 - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7071602
L1 - https://www.mdpi.com/2076-3425/10/2/97/pdf
PB - Multidisciplinary Digital Publishing Institute (MDPI)
PY - 2020
SN - 20763425
SP - 97
TI - Factors Moderating the Association Between Cannabis Use and Psychosis Risk: A Systematic Review.
UR - https://lens.org/012-151-107-325-934
VL - 10
ER -
TY - JOUR
AB - This study aimed to systematically review the prognostic value of pretransplant 18F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in refractory/relapsed Hodgkin lymphoma treated with autologous stem cell transplantation (SCT). MEDLINE was systematically searched for appropriate studies. Included studies were methodologically appraised. Results of individual studies were meta-analyzed, if possible. Eleven studies, comprising a total of 745 refractory/relapsed Hodgkin lymphoma patients who underwent FDG-PET before autologous SCT, were included. The overall methodological quality of these studies was moderate. The proportion of pretransplant FDG-PET positive patients ranged between 25 and 65.2 %. Progression-free survival ranged between 0 and 52 % in pretransplant FDG-PET positive patients, and between 55 and 85 % in pretransplant FDG-PET negative patients. Overall survival ranged between 17 and 77 % in pretransplant FDG-PET positive patients, and between 78 and 100 % in FDG-PET negative patients. Based on five studies that provided sufficient data for meta-analysis, pooled sensitivity and specificity of pretransplant FDG-PET in predicting treatment failure (i.e., either progressive, residual, or relapsed disease) were 67.2 % (95 % confidence interval [CI] 58.2–75.3 %) and 70.7 % (95 % CI 64.2–76.5 %), respectively. Based on two studies that provided sufficient data for meta-analysis, pooled sensitivity and specificity of pretransplant FDG-PET in predicting death during follow-up were 74.4 % (95 % CI 58.8–86.5 %) and 58.0 % (95 % CI 49.3–66.3 %), respectively. In conclusion, the moderate quality evidence suggests pretransplant FDG-PET to have value in predicting outcome in refractory/relapsed Hodgkin lymphoma patients treated with autologous SCT. Nevertheless, a considerable proportion of pretransplant FDG-PET positive patients remains disease free and a considerable proportion of pretransplant FDG-PET negative patients develops disease relapse after autologous SCT.
AU - Adams, Hugo J. A.
AU - Kwee, Thomas C.
CY - Germany
DA - 2016/03/02
DO - 10.1007/s00277-016-2619-9
EP - 706
ID - 012-702-845-049-503
IS - 5
JF - Annals of hematology
KW - Autologous stem cell transplantation
KW - FDG-PET
KW - Hodgkin lymphoma
KW - Meta-analysis
KW - Systematic review
L2 - http://dspace.library.uu.nl/handle/1874/342747
L2 - https://core.ac.uk/display/81087861
L2 - https://www.narcis.nl/publication/RecordID/oai%3Adspace.library.uu.nl%3A1874%2F342747
L2 - https://www.ncbi.nlm.nih.gov/pubmed/26931115
L2 - https://rd.springer.com/article/10.1007/s00277-016-2619-9
L2 - http://www.ncbi.nlm.nih.gov/pubmed/26931115
L1 - https://link.springer.com/content/pdf/10.1007%2Fs00277-016-2619-9.pdf
L2 - https://pubmed.ncbi.nlm.nih.gov/26931115/
L2 - https://link.springer.com/article/10.1007/s00277-016-2619-9
L2 - http://europepmc.org/abstract/MED/26931115
PB - Springer Verlag
PY - 2016
SN - 14320584
SN - 09395555
SP - 695
TI - Prognostic value of pretransplant FDG-PET in refractory/relapsed Hodgkin lymphoma treated with autologous stem cell transplantation: systematic review and meta-analysis
UR - https://lens.org/012-702-845-049-503
VL - 95
ER -
TY - JOUR
AB - Animal intestines are the source of edible sausage casings, which are traded worldwide and may come from areas where notifiable infectious animal diseases are prevalent. To estimate the risks of virus contamination, knowledge about the quantity of virus and decimal reduction values of the standard preservation method by salting is of great importance. A literature search, based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, was performed in search engine CAB Abstracts to determine the viral load of 14 relevant animal viruses in natural casings or intestines. Only a very limited number of scientific publications per virus were found and viral loads in the intestines varied from high for ASFV (five publications), BVDV (3), CSFV (6), PPRV (3), RPV (2) and TGEV (3) to moderate for PEDV (2) and SVDV (3), low for HEV (2) and FMDV (5), very low for VESV (1) and negative for PrV (2) and VSV (1). PRRSV was found in intestines, however, viral titers were not published. Three viruses (BVDV, CSFV and PPRV) with high viral loads were selected to search for their inactivation kinetics. For casings, no inactivation data were found, however, thermal inactivation data of these viruses were available, but differed in quantity, quality and matrices. In conclusion, important data gaps still exist when it comes to the quantitative inactivation of viruses in sausage casings or livestock intestines.
AU - Jelsma, Tinka
AU - Wijnker, Joris J.
AU - van der Poel, Wim H.M.
AU - Wisselink, Henk J.
CY - Switzerland
DA - 2021/02/04
DO - 10.3390/pathogens10020173
ID - 014-835-447-432-613
IS - 2
JF - Pathogens (Basel, Switzerland)
KW - D-value
KW - animal viruses
KW - inactivation
KW - intestines
KW - natural casings
KW - titers
KW - viral loads
L2 - https://europepmc.org/article/MED/33557372
L2 - https://pubmed.ncbi.nlm.nih.gov/33557372/
L1 - https://www.mdpi.com/2076-0817/10/2/173/pdf
L2 - https://www.narcis.nl/publication/RecordID/oai%3Alibrary.wur.nl%3Awurpubs%2F578754
L2 - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7915499/
L2 - https://www.mdpi.com/2076-0817/10/2/173
PB - MDPI AG
PY - 2021
SN - 20760817
SP - 173
TI - Intestinal Viral Loads and Inactivation Kinetics of Livestock Viruses Relevant for Natural Casing Production: a Systematic Review and Meta-Analysis.
UR - https://lens.org/014-835-447-432-613
VL - 10
ER -
TY - JOUR
AB - Background
Myocardial Infarction (MI) has become a major cause of morbidity and mortality in China, but little is known about the prevalence of guideline-recommended cardiovascular medications after MI events over the last two decades. This systematic review and meta-analysis aims to summarize cardiovascular medication use between 1995–2015 and to assess factors in associated with the trends in cardiovascular medications.
Method
A systematic search was conducted in four databases (Pubmed, Embase, CENTRAL, and CNKI) to obtain observational studies published between 1995 and 2015, reporting on the use of cardiovascular medications in China. Risk of bias of individual studies was appraised and selected studies were pooled for estimated prevalence of cardiovascular medication. Prevalence of cardiovascular medication use for 1995 and 2015 was estimated by random effects meta-regression model.
Results
From 13,940 identified publications, 35 studies, comprising 28,000 patients, were included. The pooled prevalence for aspirin, beta-blockers, statins, ACE-Inhibitors, ACE-Inhibitor/ARBs and nitrates was 92% [95% confidence interval (CI): 0.89–0.95], 63% (95% CI: 0.57–0.69), 72% (95% CI: 0.60–0.82), 49% (95% CI: 0.41–0.57), 59% (95% CI: 0.48–0.69) and 79% (95% CI: 0.74–0.91), respectively. A significant increase in beta-blocker and statin use and a decrease of nitrate use was observed over time. The estimated prevalence of beta-blockers, statins, and nitrates was 78%, 91.1%, and 59.3% in 2015, compared to 32%, 17% and 96% in 1995, respectively.
Conclusion
Cardiovascular medication use after MI is far from optimal in Chinese patients, even though the prevalence of use increased over the period 1995–2015. With a rapidly increasing number of MI patients in China, a comprehensive strategy on secondary prevention is warranted.
Systematic review registration
PROSPERO (CRD42015025246)
AU - Zhao, Min
AU - Klipstein-Grobusch, Kerstin
AU - Wang, Xin
AU - Reitsma, Johannes B.
AU - Zhao, Dong
AU - Grobbee, Diederick E.
AU - Graham, Ian
AU - Vaartjes, Ilonca
CY - United States
DA - 2017/04/20
DO - 10.1371/journal.pone.0175947
ID - 015-430-936-175-938
IS - 4
JF - PloS one
L2 - https://doaj.org/article/76334272aedf498aa966cc45ff620054
L2 - https://dspace.library.uu.nl/handle/1874/348907
L2 - https://dx.plos.org/10.1371/journal.pone.0175947
L2 - https://ui.adsabs.harvard.edu/abs/2017PLoSO..1275947Z/abstract
L2 - https://europepmc.org/abstract/MED/28426793
L2 - https://pubmed.ncbi.nlm.nih.gov/28426793/
L2 - https://www.narcis.nl/publication/RecordID/oai%3Apure.amc.nl%3Apublications%2F7e46eb18-fdcb-4ca3-971f-98cb15cebc67
L2 - https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0175947
L2 - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5398555
PB - Public Library of Science
PY - 2017
SN - 19326203
SP - e0175947
TI - Prevalence of cardiovascular medication on secondary prevention after myocardial infarction in China between 1995-2015 : A systematic review and meta-analysis
UR - https://lens.org/015-430-936-175-938
VL - 12
ER -
TY - JOUR
AB - Background The Millennium Developmental Goals ensured a significant reduction in childhood mortality. However, this reduction simultaneously raised concerns about the long-term outcomes of survivors of early childhood insults. This systematic review focuses on the long-term neurocognitive and mental health outcomes of neonatal insults (NNI) survivors who are six years or older. Methods Two independent reviewers conducted a comprehensive search for empirical literature by combining index and free terms from the inception of the databases until 10th October 2019. We also searched for additional relevant literature from grey literature and using reference tracking. Studies were included if they: were empirical studies conducted in humans; the study participants were followed at six years of age or longer; have an explicit diagnosis of NNI, and explicitly define the outcome and impairment. Medians and interquartile range (IQR) of the proportions of survivors of the different NNI with any impairment were calculated. A random-effect model was used to explore the estimates accounted for by each impairment domain. Results Fifty-two studies with 94,978 participants who survived NNI were included in this systematic review. The overall prevalence of impairment in the survivors of NNI was 10.0% (95% CI 9.8–10.2). The highest prevalence of impairment was accounted for by congenital rubella (38.8%: 95% CI 18.8–60.9), congenital cytomegalovirus (23.6%: 95% CI 9.5–41.5), and hypoxic-ischemic encephalopathy (23.3%: 95% CI 14.7–33.1) while neonatal jaundice has the lowest proportion (8.6%: 95% CI 2.7–17.3). The most affected domain was the neurodevelopmental domain (16.6%: 95% CI 13.6–19.8). The frequency of impairment was highest for neurodevelopmental impairment [22.0% (IQR = 9.2–24.8)] and least for school problems [0.0% (IQR = 0.0–0.00)] in any of the conditions. Conclusion The long-term impact of NNI is also experienced in survivors of NNI who are 6 years or older, with impairments mostly experienced in the neurodevelopmental domain. However, there are limited studies on long-term outcomes of NNI in sub-Saharan Africa despite the high burden of NNI in the region. Trial registration Registration number: CRD42018082119.
AU - Magai, Dorcas N.
AU - Karyotaki, Eirini
AU - Mutua, Agnes M.
AU - Chongwo, Esther
AU - Nasambu, Carophine
AU - Ssewanyana, Derrick
AU - Newton, Charles R.
AU - Koot, Hans M.
AU - Abubakar, Amina
CY - United States
DA - 2020/04/24
DO - 10.1371/journal.pone.0231947
EP - 16
ID - 015-720-710-260-350
IS - 4
JF - PloS one
L2 - https://www.narcis.nl/publication/RecordID/oai%3Aresearch.vu.nl%3Apublications%2F3d7597db-8b59-45e9-b007-5769ae184076
L2 - https://www.tropicalmedicine.ox.ac.uk/publications/1103232
L1 - https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0231947&type=printable
L2 - https://works.bepress.com/amina_abubakar/31/
L2 - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7182387
L2 - https://ecommons.aku.edu/eastafrica_ihd/56/
L2 - https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0231947
L1 - https://ecommons.aku.edu/cgi/viewcontent.cgi?article=1055&context=eastafrica_ihd
L2 - http://www.ncbi.nlm.nih.gov/pubmed/32330163
L2 - https://pubmed.ncbi.nlm.nih.gov/32330163/
L2 - https://www.psych.ox.ac.uk/publications/1103232
L2 - https://research.vu.nl/en/publications/long-term-outcomes-of-survivors-of-neonatal-insults-a-systematic-
L2 - http://ui.adsabs.harvard.edu/abs/2020PLoSO..1531947M/abstract
L2 - https://dx.plos.org/10.1371/journal.pone.0231947
L2 - https://plos.figshare.com/collections/Long-term_outcomes_of_survivors_of_neonatal_insults_A_systematic_review_and_meta-analysis/4952631
PB - Public Library of Science
PY - 2020
SN - 19326203
SP - 1
TI - Long-term outcomes of survivors of neonatal insults: A systematic review and meta-analysis
UR - https://lens.org/015-720-710-260-350
VL - 15
ER -
TY - JOUR
AB - Abstract Innovations accompanying transitions often prompt institutional change if they do not match with existing institutions. Transition studies started to incorporate institutional dynamics into their research, but efforts hitherto remain underdeveloped. In this paper, we systematically review the institutional entrepreneurship literature. Based on a reading of 153 empirical cases, we identify trends and biases in the literature and we distil a number of insights for transition studies to engage with.
AU - Hoogstraaten, Marjolein J.
AU - Frenken, Koen
AU - Boon, Wouter
CY - Netherlands
DO - 10.1016/j.eist.2020.05.004
EP - 136
ID - 016-598-600-357-16X
JF - Environmental Innovation and Societal Transitions
L2 - https://www.sciencedirect.com/science/article/abs/pii/S221042242030085X
L2 - https://www.sciencedirect.com/science/article/pii/S221042242030085X
PB - Elsevier BV
PY - 2020
SN - 22104224
SP - 114
TI - The study of institutional entrepreneurship and its implications for transition studies
UR - https://lens.org/016-598-600-357-16X
VL - 36
ER -
TY - JOUR
AB - BACKGROUND AND AIMS Studies examining the next-day cognitive effects of heavy alcohol consumption have produced mixed findings, which may reflect inconsistencies in definitions of 'hangover'. Recent consensus has defined hangover as 'mental and physical symptoms, experienced the day after a single episode of heavy drinking, starting when blood alcohol concentration (BAC) approaches zero'. In light of this, we aimed to review the literature systematically to evaluate and estimate mean effect sizes of the next-day effects of heavy alcohol consumption on cognition. METHODS Embase, PubMed and PsycNET databases were searched between December 2016 and May 2018 using terms based on 'alcohol' and 'hangover'. Studies of experimental designs which reported the next-day cognitive effects of heavy alcohol consumption in a 'hangover' group with BAC < 0.02% were reviewed. A total of 805 articles were identified. Thirty-nine full-text articles were screened by two independent reviewers and 19 included in the systematic review; 11 articles provided sufficient data to be included in the meta-analysis; 1163 participants across 19 studies conducted since 1970 were included in the analysis. Data for study design, hangover severity, BAC at testing and cognitive performance were extracted and effect estimates calculated. RESULTS The systematic review suggested that sustained attention and driving abilities were impaired during hangover. Mixed results were observed for: psychomotor skills, short- (STM) and long-term memory (LTM) and divided attention. The meta-analysis revealed evidence of impairments in STM [g = 0.64, 95% confidence interval (CI) = 0.15-1.13], LTM (Hedges' g = 0.59, 95% CI = 0.01-1.17) sustained attention (g = 0.47, 95% CI = 0.07-0.87) and psychomotor speed (Hedges' g = 0.66, 95% CI = 0.31-1.00) during alcohol hangover. CONCLUSION The research literature suggests that alcohol hangovers may involve impaired cognitive functions and performance of everyday tasks such as driving.
AU - Gunn, Craig
AU - Mackus, Marlou
AU - Griffin, Christopher T.
AU - Munafò, Marcus R.
AU - Adams, Sally
CY - United Kingdom
DA - 2018/08/30
DO - 10.1111/add.14404
EP - 2193
ID - 017-249-029-664-064
IS - 12
JF - Addiction (Abingdon, England)
KW - Alcohol
KW - cognition
KW - driving
KW - hangover
KW - memory
KW - psychomotor
KW - sustained attention
L1 - https://onlinelibrary.wiley.com/doi/pdf/10.1111/add.14404
L2 - https://research-information.bristol.ac.uk/en/publications/a-systematic-review-of-the-nextday-effects-of-heavy-alcohol-consumption-on-cognitive-performance(c60e3742-e8d5-4087-a586-c9788ad31b79).html
L2 - https://researchportal.bath.ac.uk/en/publications/a-systematic-review-of-the-next-day-effects-of-heavy-alcohol-cons
L2 - https://onlinelibrary.wiley.com/doi/full/10.1111/add.14404
L1 - https://research-information.bris.ac.uk/files/168632323/Gunn_et_al_2018_Addiction.pdf
L2 - https://europepmc.org/article/MED/30144191
L2 - https://pubmed.ncbi.nlm.nih.gov/30144191/
L2 - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282576
L2 - https://research-information.bris.ac.uk/en/publications/a-systematic-review-of-the-next-day-effects-of-heavy-alcohol-cons
L2 - https://www.ncbi.nlm.nih.gov/pubmed/30144191
L2 - https://research-information.bris.ac.uk/en/publications/a-systematic-review-of-the-nextday-effects-of-heavy-alcohol-consumption-on-cognitive-performance(c60e3742-e8d5-4087-a586-c9788ad31b79).html
L2 - https://core.ac.uk/download/161257769.pdf
PB - Wiley-Blackwell
PY - 2018
SN - 13600443
SN - 09652140
SP - 2182
TI - A systematic review of the next-day effects of heavy alcohol consumption on cognitive performance.
UR - https://lens.org/017-249-029-664-064
VL - 113
ER -
TY - JOUR
AB - Introduction: Intraoperatively obtained peri-implant tissue cultures remain the standard for diagnosis of fracture-related infection (FRI), although culture-negative cases may complicate treatment decisions. This paper reviews the evidence on sonication fluid and tissue sampling for the diagnosis of FRI. Methods: A comprehensive search in Pubmed, Embase and Web-of-Science was carried out on April 5, 2018, to identify diagnostic validation studies regarding sonication fluid and tissue sampling for FRI. Results: Out of 2624 studies, nine fulfilled the predefined inclusion criteria. Five studies focused on sonication fluid culture, two on PCR and two on histopathology. One additional histopathology study was found after screening of reference lists. There is limited evidence that sonication fluid culture may be a useful adjunct to conventional tissue culture, but no strong evidence that it is superior or can replace tissue culture. Regarding molecular techniques and histopathology the evidence is even less clear. Overall, studies had variable 'gold standard' criteria for comparison and poorly reported culture methods. Conclusions: Scientific evidence on sonication fluid and tissue sampling, including culture, molecular techniques and histopathology for the diagnosis of FRI is scarce. It is imperative that laboratory protocols become standardized and uniform diagnostic criteria, as recently published in a consensus definition, be implemented.
AU - Onsea, Jolien
AU - Depypere, Melissa
AU - Govaert, Geertje A M
AU - Kuehl, Richard
AU - Vandendriessche, Thomas
AU - Morgenstern, Mario
AU - McNally, Martin A.
AU - Trampuz, Andrej
AU - Metsemakers, Willem-Jan
CY - Germany
DA - 2018/08/10
DO - 10.7150/jbji.27840
EP - 181
ID - 017-805-104-132-741
IS - 4
JF - Journal of bone and joint infection
KW - Fracture-related infection
KW - diagnosis
KW - histopathology
KW - sonication
KW - systematic review
KW - tissue sampling
L1 - https://jbji.copernicus.org/articles/3/173/2018/jbji-3-173-2018.pdf
L2 - https://europepmc.org/article/MED/30155402
L2 - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6098816
L2 - https://pubmed.ncbi.nlm.nih.gov/30155402/
L1 - https://lirias.kuleuven.be/retrieve/575505
L2 - http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6098816
L2 - https://jbji.copernicus.org/articles/3/173/2018/
PB - Copernicus GmbH
PY - 2018
SN - 22063552
SP - 173
TI - Accuracy of Tissue and Sonication Fluid Sampling for the Diagnosis of Fracture-Related Infection: A Systematic Review and Critical Appraisal.
UR - https://lens.org/017-805-104-132-741
VL - 3
ER -
TY - JOUR
AB - Background and Purpose: Hypercoagulability increases the risk of arterial thrombosis; however, this effect may differ between various manifestations of arterial disease. Methods: In this study, we compared the effect of coagulation factors asmeasures of hypercoagulability on the risk of ischaemic stroke (IS) and myocardial infarction (MI) by performing a systematic review of the literature. The effect of a risk factor on IS (relative risk for IS, RR IS ) was compared with the effect on MI (RR MI ) by calculating their ratio (RRR = RR IS /RR MI ). A relevant differential effect was considered when RRR was >1+ its own standard error (SE) or 1+1SE) was found in 49/343 (14%) markers. Of these, 18/49 (37%) had an RRR greater than 1+2SE. On the opposite side, a larger effect on MI risk (RRR<1-1SE) was found in only 17/343 (5%) markers. Conclusions: These results suggest that hypercoagulability has a more pronounced effect on the risk of IS than that of MI.
AU - Maino, Alberto
AU - Rosendaal, Frits R.
AU - Algra, Ale
AU - Peyvandi, Flora
AU - Siegerink, Bob
CY - United States
DA - 2015/08/07
DO - 10.1371/journal.pone.0133523
EP - 12
ID - 017-900-945-434-221
IS - 8
JF - PloS one
L2 - https://paperity.org/p/73825602/hypercoagulability-is-a-stronger-risk-factor-for-ischaemic-stroke-than-for-myocardial
L2 - https://doaj.org/article/610b49d828a248959939a179d92cdc0a
L2 - https://www.narcis.nl/publication/RecordID/oai%3Adspace.library.uu.nl%3A1874%2F332037
L2 - https://air.unimi.it/handle/2434/429876
L2 - http://ui.adsabs.harvard.edu/abs/2015PLoSO..1033523M/abstract
L2 - https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0133523
L2 - http://www.ncbi.nlm.nih.gov/pubmed/26252207
L2 - https://moh-it.pure.elsevier.com/en/publications/hypercoagulability-is-a-stronger-risk-factor-for-ischaemic-stroke
L2 - https://dx.plos.org/10.1371/journal.pone.0133523
L2 - http://dspace.library.uu.nl/handle/1874/332037
L2 - https://pubmed.ncbi.nlm.nih.gov/26252207/
L2 - https://europepmc.org/articles/PMC4529149
L2 - https://core.ac.uk/display/39823679
PB - Public Library of Science
PY - 2015
SN - 19326203
SP - 1
TI - Hypercoagulability Is a Stronger Risk Factor for Ischaemic Stroke than for Myocardial Infarction: A Systematic Review
UR - https://lens.org/017-900-945-434-221
VL - 10
ER -
TY - JOUR
AB - Recognizing the robust sex differences in schizophrenia prevalence, the selective estrogen receptor modulator (SERM) raloxifene is a likely candidate for augmentation therapy in this disorder. Therefore, a systematic search was performed using PubMed (Medline), Embase, PsychInfo, and Cochrane Database of Systematic Reviews. Randomized controlled trials investigating the effect of raloxifene in schizophrenia spectrum disorders were included in the quantitative analyses. Outcome measures were psychotic symptom severity, depression, and cognition. Meta-analyses were performed using Comprehensive Meta-Analysis software. A random-effects model was used to compute overall weighted effect sizes in Hedges’ g. Nine studies were included, investigating 561 patients with a schizophrenia spectrum disorder. Raloxifene was superior to placebo in improving total symptom severity (N = 482; Hedge’s g = .57, p = 0.009), as well as positive (N = 561; Hedge’s g = 0.32, p = 0.02), negative (N = 561; Hedge’s g = 0.40, p = 0.02), and general (N = 526; Hedge’s g = 0.46, p = 0.01) subscales, as measured by the Positive and Negative Syndrome Scale. No significant effects were found for comorbid depression and cognitive functioning. Altogether, these results confirm the potential of raloxifene augmentation in the treatment of schizophrenia.
AU - de Boer, Janna
AU - Prikken, Merel
AU - Lei, Wan U.
AU - Begemann, Marieke J.H.
AU - Sommer, Iris E. C.
CY - United States
DA - 2018/01/10
DO - 10.1038/s41537-017-0043-3
EP - 6
ID - 020-206-392-856-827
IS - 1
JF - NPJ schizophrenia
L2 - https://www.narcis.nl/publication/RecordID/oai%3Apure.rug.nl%3Apublications%2F705141e1-03fc-48db-8415-40c79e4de8d4
L2 - https://europepmc.org/articles/PMC5762671
L2 - https://www.nature.com/articles/s41537-017-0043-3
L2 - https://www.ncbi.nlm.nih.gov/pubmed/29321530
L2 - https://www.nature.com/articles/s41537-017-0043-3.pdf
L2 - https://pubmed.ncbi.nlm.nih.gov/29321530/
L2 - https://www.rug.nl/research/portal/files/71240608/s41537_017_0043_3.pdf
PB - Springer Science and Business Media LLC
PY - 2018
SN - 2334265x
SP - 1
TI - The effect of raloxifene augmentation in men and women with a schizophrenia spectrum disorder: a systematic review and meta-analysis.
UR - https://lens.org/020-206-392-856-827
VL - 4
ER -
TY - JOUR
AB - Carotid stent (CS) characteristics, such as radial force, scaffolding and flexibility, are continuously modified by stent manufacturers aiming to improve stent performance. Since manufacturers’ definitions and assessment methods are not disclosed, it is unknown how characteristics of different CSs relate to each other or to published literature. We examined in vitro methodological techniques used to measure CS characteristics and assessed comparability between published papers and outcomes as provided by the manufacturers. A systematic review was conducted in MEDLINE, Embase, Cochrane, and Scopus databases. Studies reporting on in vitro investigations of predefined characteristics of CS used in current everyday clinical practice were included. The predefined characteristics were radial force, scaffolding, flexibility, foreshortening, side-branch preservation and visibility. Eight manufacturers of 10 currently used CS were contacted and data on the predefined device characteristics was requested. 12 published articles were included and six stent manufacturers provided data on six stents (two refused to share data). Used methodologies to measure stent characteristics in published literature and manufacturer data varied greatly for all included characteristics except foreshortening. The number of different units of measurement to express outcomes ranged from two for foreshortening to six for radial force. A variety of methodologies and outcome measures is used to quantify CS characteristics, which hampers comparisons between published studies and manufacturer data. Future studies are encouraged to synchronize methodologies and outcome measures. Manufacturers are encouraged up to increase transparency of applied testing methodologies and outcomes.
AU - de Vries, Evelien E.
AU - Kök, Mert
AU - Hoving, Astrid M.
AU - Slump, Cornelis H.
AU - Toorop, Raechel J.
AU - de Borst, Gert J.
CY - Germany
DA - 2020/05/14
DO - 10.1007/s00270-020-02499-1
EP - 1437
ID - 020-544-765-969-94X
IS - 10
JF - Cardiovascular and interventional radiology
KW - Carotid artery stent
KW - Carotid stenosis
KW - In vitro testing
KW - Mechanical behavior
KW - Systematic review
L2 - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7524852
L2 - https://link.springer.com/article/10.1007/s00270-020-02499-1
L2 - https://www.narcis.nl/publication/RecordID/oai%3Aris.utwente.nl%3Apublications%2F8c5752c3-369d-4179-b092-4b5008c4436d
L2 - https://pubmed.ncbi.nlm.nih.gov/32409999/
L2 - https://research.utwente.nl/en/publications/incomparability-of-carotid-artery-stent-characteristics-a-systema
L1 - https://link.springer.com/content/pdf/10.1007/s00270-020-02499-1.pdf
PB - Springer Verlag
PY - 2020
SN - 1432086x
SN - 01741551
SN - 74155101
SP - 1430
TI - (In)comparability of Carotid Artery Stent Characteristics: A Systematic Review on Assessment and Comparison with Manufacturer Data
UR - https://lens.org/020-544-765-969-94X
VL - 43
ER -
TY - JOUR
AB - Background In adult immune thrombocytopenia (ITP), an acquired autoimmune bleeding disorder, anti-platelet autoantibody testing may be useful as a rule-in test. Childhood ITP has different disease characteristics, and the diagnostic and prognostic value of anti-platelet antibody testing remains uncertain. Objective To systematically review the diagnostic accuracy of anti-platelet autoantibody testing in childhood ITP. Methods PubMed and EMBASE were searched for studies evaluating immunoassays in childhood ITP. Study quality was assessed (QUADAS2), and evidence was synthesized descriptively. Results In total, 40 studies (1606 patients) were identified. Nine studies reported sufficient data to determine diagnostic accuracy measures. Anti-platelet IgG antibody testing showed a moderate sensitivity (0·36-0·80 platelet-associated IgG [direct test]; 0·19-0·39 circulating IgG [indirect test]). In studies that reported control data, including patients with non-immune thrombocytopenia, specificity was very good (0·80-1·00). Glycoprotein-specific immunoassays showed comparable sensitivity (three studies) and predominantly identified IgG anti-GP IIb/IIIa antibodies, with few IgG anti-GP Ib/IX antibodies. Anti-platelet IgM antibodies were identified in a substantial proportion of children (sensitivity 0·62-0·64 for direct and indirect tests). Conclusion The diagnostic evaluation of IgG and IgM anti-platelet antibodies may be useful as a rule-in test for ITP. In children with insufficient platelets for a direct test, indirect tests may be performed instead. A negative test does not rule out the diagnosis of ITP. Future studies should evaluate the value of anti-platelet antibody tests in thrombocytopenic children with suspected ITP.
AU - Schmidt, David E.
AU - Lakerveld, Anke J.
AU - Heitink-Pollé, Katja M. J.
AU - Bruin, Marrie C. A.
AU - Vidarsson, Gestur
AU - Porcelijn, Leendert
AU - de Haas, Masja
CY - United Kingdom
DA - 2020/02/20
DO - 10.1111/vox.12894
EP - 333
ID - 021-366-327-335-290
IS - 4
JF - Vox sanguinis
KW - autoantibodies
KW - clinical laboratory techniques
KW - immune thrombocytopenia
KW - paediatrics
KW - systematic review
L2 - https://onlinelibrary.wiley.com/doi/10.1111/vox.12894
L2 - https://pubmed.ncbi.nlm.nih.gov/32080872/
L2 - https://europepmc.org/article/MED/32080872
L2 - https://www.ncbi.nlm.nih.gov/pubmed/32080872
L2 - https://www.narcis.nl/publication/RecordID/oai%3Apure.amc.nl%3Apublications%2F3f723d08-6de0-47db-a39a-7bc880eb50b0
PB - Wiley-Blackwell
PY - 2020
SN - 14230410
SN - 00429007
SP - 323
TI - Anti‐platelet antibody immunoassays in childhood immune thrombocytopenia: a systematic review
UR - https://lens.org/021-366-327-335-290
VL - 115
ER -
TY - JOUR
AB - Abstract Hemophilic arthropathy (HA) causes major morbidity. Breakthrough therapies reduce the bleeding frequency tremendously, but well-defined joint outcome assessments with a focus on early changes and subclinical damage are lacking. Biomarkers reflecting joint tissue turnover/inflammation might be useful to predict invalidating arthropathy. This systematic review summarized and categorized publications on blood/urinary biomarkers in HA to provide leads for implementation. A PubMed/EMBASE search was performed on September 9, 2019. All publications were assessed and allocated to one or several BIPED-categories, based on the utility of biomarkers. Of the initial 1307 publications found, 27 were eligible for inclusion. The majority (81%, n = 32/42) was cross-sectional in design, including relatively small numbers of patients (median 44, interquartile range 35–78). Fourteen percent (n = 6/42) investigated dynamic changes around a bleeding or treatment. Only two studies investigated the prognostic value of biomarkers. Most promising biomarkers were serum Coll2-1, COL-18N, COMP, C1,2C, C2M, CS846, MIF, plasma sVCAM-1 and urinary CTX-II. Comparing performances and pooling data was not possible due to heterogeneity. Currently, biomarker research in HA is still in an explorative stage and not yet sufficient for translation into daily practice. Clearly, larger homogeneous longitudinal studies in well-defined populations should be performed for further development.
AU - van Bergen, E.D.P.
AU - van Vulpen, L. F. D.
AU - Schutgens, Roger E. G.
AU - Mastbergen, Simon C.
AU - Lafeber, F.P.J.G.
CY - United States
DA - 2020/11/22
DO - 10.1016/j.blre.2020.100781
ID - 023-029-695-165-796
JF - Blood reviews
KW - BIPED - Hemophilic arthropathy
KW - Biochemical markers
KW - Inflammation
KW - Joint tissue turnover
L2 - https://www.ncbi.nlm.nih.gov/pubmed/33277057
L2 - https://www.sciencedirect.com/science/article/pii/S0268960X20301314
L2 - https://pubmed.ncbi.nlm.nih.gov/33277057/
L2 - https://www.sciencedirect.com/science/article/abs/pii/S0268960X20301314
PB - Churchill Livingstone
PY - 2020
SN - 15321681
SN - 0268960x
SP - 100781
TI - Biochemical marker research in hemophilic arthropathy: A systematic review.
UR - https://lens.org/023-029-695-165-796
VL - 47
ER -
TY - JOUR
AB - Increased awareness and understanding of current practices in translational research is required for informed decision making in drug development. This paper describes a systematic review of methotrexate for rheumatoid arthritis, comparing trial design between 147 animal and 512 human studies. Animal studies generally included fewer subjects than human studies, and less frequently reported randomisation and blinding. In relation to life span, study duration was comparable for animals and humans, but included animals were younger than included humans. Animal studies often comprised males only (61%), human studies always included females (98% included both sexes). Power calculations were poorly reported in both samples. Analyses of human studies more frequently comprised Chi-square tests, those of animal studies more frequently reported analyses of variance. Administration route was more variable, and more frequently reported in animal than human studies. Erythrocyte sedimentation rate and c-reactive protein were analysed more frequently in human than in animal studies. To conclude, experimental designs for animal and human studies are not optimally aligned. However, methotrexate is effective in treating rheumatoid arthritis in animal models and humans. Further evaluation of the available evidence in other research fields is needed to increase the understanding of translational success before we can optimise translational strategies.
AU - Leenaars, Cathalijn H. C.
AU - Stafleu, F.R.
AU - de Jong, David
AU - van Berlo, Maikel
AU - Geurts, Tijmen